[-] Show simple item record

dc.contributor.advisorTanner, John J., 1961-eng
dc.contributor.authorChristensen, Emily M.eng
dc.date.issued2019eng
dc.date.submitted2019 Summereng
dc.descriptionIncludes vitaeng
dc.description.abstract[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT REQUEST OF AUTHOR.] Pyrroline-5-carboxylate reductase (PYCR) is the final enzyme in proline biosynthesis, catalyzing the NAD(P)H-dependent reduction of [Delta]1-pyrroline-5-carboxylate (P5C) to proline. Mutations in the PYCR1 gene alter mitochondrial function and cause the connective tissue disorder cutis laxa. Furthermore, PYCR1 is overexpressed in multiple cancers, and the PYCR1 knockout suppresses tumorigenic growth, suggesting PYCR1 is a potential cancer target. However, inhibitor development has been stymied by limited mechanistic details for the enzyme, particularly in light of a previous crystallographic study that placed the cofactor binding site in the C-terminal domain rather than the anticipated Rossmann fold of the N-terminal domain. To fill this gap, we report crystallographic, sedimentation velocity, and kinetics data for human PYCR1. Structures of binary complexes of PYCR1 with NADPH or proline determined at 1.9 A resolution provide insight into cofactor and substrate recognition. We see NADPH bound to the Rossmann fold, over 25 A from the previously proposed site. The 1.85 A resolution structure of a ternary complex containing NADPH and a P5C/proline analog provides a model of the Michaelis complex formed during hydride transfer. Sedimentation velocity shows that PYCR1 forms a concentration-dependent decamer in solution, consistent with the pentamer-of-dimers assembly seen crystallographically. Kinetic and mutational analysis confirmed several features seen in the crystal structure, including the importance of a hydrogen bond between Thr238 and the substrate as well as limited cofactor discrimination. We also report kinetic and structural data for PYCR1 complexed with multiple P5C/Pro analogs to probe the potential of PYCR1 as a cancer therapy target. Crystal structures of binary complexes of PYCR1 with L-tetrahydro-2-furoic acid (THFA),N-formyl L-proline (NFLP), thiazolidine-2-carboxylate (T2C), and thiazolidine-4-carboxylate (T4C) have been determined at 1.80-2.35 A resolution. We also present inhibition data for the forward reaction of P5C reduction to proline in the presence of each analog.eng
dc.description.bibrefIncludes bibliographical referenceseng
dc.format.extentxii, 99 pages : illustrationseng
dc.identifier.urihttps://hdl.handle.net/10355/76143
dc.identifier.urihttps://doi.org/10-32469/10355/76143eng
dc.languageEnglisheng
dc.publisherUniversity of Missouri--Columbiaeng
dc.relation.ispartofcommunityUniversity of Missouri--Columbia. Graduate School. Theses and Dissertationseng
dc.rightsAccess to files is limited to the University of Missouri--Columbia.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.
dc.subject.otherPyrroline-5-carboxylate reductaseeng
dc.subject.otherProline biosynthesiseng
dc.subject.otherTumorigenic growtheng
dc.subject.otherSedimentation velocityeng
dc.subject.otherChemistryeng
dc.subject.otherBiologyeng
dc.titleStructural, biochemical, and inhibition studies of proline biosynthetic enzymeseng
dc.typeThesiseng
thesis.degree.disciplineChemistry (MU)eng
thesis.degree.grantorUniversity of Missouri--Columbiaeng
thesis.degree.levelDoctoraleng
thesis.degree.namePh. D.eng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record